ACT-16 THE POTENTIAL OF HYPOFRACTIONATED RADIOTHERAPY AND BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT

INTRODUCTION: First-line bevacizumab (BEV) is now available as a treatment option for glioblastoma (GBM) patients with severe clinical conditions in Japan. However, the survival benefits remain controversial. As we have emphasized the combined effect of BEV and radiation therapy, the strategies; 1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hata, Nobuhiro, Mizoguchi, Masahiro, Kuga, Daisuke, Hatae, Ryusuke, Sangatsuda, Yuhei, Akagi, Yojiro, Amemiya, Takeo, Fujioka, Yutaka, Takigawa, Kosuke, Yoshitake, Tadamasa, Yoshimoto, Koji, Iihara, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213105/
http://dx.doi.org/10.1093/noajnl/vdz039.065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213105/
http://dx.doi.org/10.1093/noajnl/vdz039.065

Ejemplares similares